FDA Rejects Drug for Chronic Cough
Pulmonology > > General Pulmonology-- Agency points out effectiveness issues in evaluation of P2X3 receptor villain gefapixant
by Ian Ingram, Managing Editor, MedPage Today December 21, 2023
The FDA decreased to authorize oral gefapixant for dealing with persistent cough, Merck revealed on Wednesday.
In its total action letter, "the FDA concluded that Merck's application did not satisfy significant proof of efficiency" for the treatment of inexplicable or refractory persistent cough, according to the drugmaker, however no security issues were mentioned.
No authorized drug exists for dealing with persistent cough, and the company...